S Goteti

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

Miguel Martín, A. Chan, Luc Dirix et al. · Annals of Oncology · 2016 · 185 citations · Full text

Medicine, Oncology, Pharmacology +15

P273 Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study

Julián Panés, W. Sandborn, Edward V. Loftus et al. · Journal of Crohn s and Colitis · 2018 · 20 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

OP022 Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the CELEST study

Stefan Schreiber, Laurent Peyrin‐Biroulet, Brigid S. Boland et al. · Journal of Crohn s and Colitis · 2018 · 14 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Interim phase 1 part A results for ALN‐APP, the first investigational RNAi therapeutic in development for Alzheimer’s disease

Sharon Cohen, Simon Ducharme, Jared R. Brosch et al. · Alzheimer s & Dementia · 2023 · 13 citations · Full text

Medicine, Neurology, Pharmacology +17

Single ascending dose results from an ongoing Phase 1 study of mivelsiran (ALN‐APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer’s disease

Sharon Cohen, Simon Ducharme, Jared R. Brosch et al. · Alzheimer s & Dementia · 2024 · 10 citations · Full text

Medicine, Neurology, Pharmacology +17